Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP for drug discovery and mechanism of action (MOA) research

Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sotatercept is a fusion protein contains extracellular domain of the human activin receptor type IIA fused with the Fc domain of human IgG1. Sotatercept acts as a ligand trap for members of the TGF-¦Â superfamily, thus restoring balance between the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway. Sotatercept has been used to treat hematologic disorders, dysfunctional TGF-¦Â superfamily signaling pathway based bone loss, chemotherapy-induced anemia, multiple myeloma, myelodysplastic syndromes, ¦Â-thalassemia, and end-stage kidney disease.